astria therapeutics inc - CPRX
CPRX
Close Chg Chg %
24.45 -0.06 -0.25%
Open Market
24.39
-0.06 (0.25%)
Volume: 299.01K
Last Updated:
Dec 26, 2025, 2:40 PM EDT
Company Overview: astria therapeutics inc - CPRX
CPRX Key Data
| Open $24.38 | Day Range 24.08 - 24.44 |
| 52 Week Range 19.05 - 26.58 | Market Cap $3.01B |
| Shares Outstanding 122.91M | Public Float 110.45M |
| Beta 0.68 | Rev. Per Employee N/A |
| P/E Ratio 14.27 | EPS $1.79 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.34M |
CPRX Performance
| 1 Week | 2.99% | ||
| 1 Month | 4.44% | ||
| 3 Months | 25.26% | ||
| 1 Year | 13.88% | ||
| 5 Years | 614.91% |
CPRX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About astria therapeutics inc - CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
CPRX At a Glance
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Coral Gables, Florida 33134
| Phone | 1-305-420-3200 | Revenue | 491.73M | |
| Industry | Pharmaceuticals: Major | Net Income | 163.89M | |
| Sector | Health Technology | 2024 Sales Growth | 23.488% | |
| Fiscal Year-end | 12 / 2025 | Employees | 181 | |
| View SEC Filings |
CPRX Valuation
| P/E Current | 14.267 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 15.911 |
| Price to Sales Ratio | 5.303 |
| Price to Book Ratio | 3.467 |
| Price to Cash Flow Ratio | 10.87 |
| Enterprise Value to EBITDA | 8.977 |
| Enterprise Value to Sales | 4.257 |
| Total Debt to Enterprise Value | 0.002 |
CPRX Efficiency
| Revenue/Employee | 2,716,762.431 |
| Income Per Employee | 905,464.088 |
| Receivables Turnover | 7.51 |
| Total Asset Turnover | 0.741 |
CPRX Liquidity
| Current Ratio | 5.168 |
| Quick Ratio | 5.006 |
| Cash Ratio | 4.289 |
CPRX Profitability
| Gross Margin | 78.398 |
| Operating Margin | 39.681 |
| Pretax Margin | 43.98 |
| Net Margin | 33.329 |
| Return on Assets | 24.712 |
| Return on Equity | 29.384 |
| Return on Total Capital | 22.425 |
| Return on Invested Capital | 29.227 |
CPRX Capital Structure
| Total Debt to Total Equity | 0.438 |
| Total Debt to Total Capital | 0.436 |
| Total Debt to Total Assets | 0.373 |
| Long-Term Debt to Equity | 0.383 |
| Long-Term Debt to Total Capital | 0.381 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Astria Therapeutics Inc - CPRX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 140.83M | 214.20M | 398.20M | 491.73M | |
Sales Growth
| +18.27% | +52.10% | +85.90% | +23.49% | |
Cost of Goods Sold (COGS) incl D&A
| 21.88M | 34.39M | 84.53M | 106.22M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 484.00K | 1.49M | 33.14M | 38.05M | |
Depreciation
| 484.00K | 388.00K | 578.00K | 675.00K | |
Amortization of Intangibles
| - | 1.10M | 32.56M | 37.38M | |
COGS Growth
| +28.43% | +57.16% | +145.78% | +25.66% | |
Gross Income
| 118.95M | 179.81M | 313.67M | 385.51M | |
Gross Income Growth
| +16.58% | +51.17% | +74.45% | +22.90% | |
Gross Profit Margin
| +84.46% | +83.94% | +78.77% | +78.40% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 66.56M | 77.97M | 226.86M | 190.39M | |
Research & Development
| 16.94M | 19.79M | 93.15M | 12.65M | |
Other SG&A
| 49.63M | 58.18M | 133.71M | 177.74M | |
SGA Growth
| +9.61% | +17.14% | +190.95% | -16.08% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (5.08M) | - |
EBIT after Unusual Expense
| 52.38M | 101.84M | 86.81M | 200.20M | |
Non Operating Income/Expense
| 282.00K | 2.88M | 7.70M | 16.06M | |
Non-Operating Interest Income
| - | - | - | 16.06M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 52.67M | 104.72M | 94.51M | 216.26M | |
Pretax Income Growth
| +25.73% | +98.83% | -9.75% | +128.82% | |
Pretax Margin
| +37.40% | +48.89% | +23.73% | +43.98% | |
Income Tax
| 13.19M | 21.64M | 23.10M | 52.37M | |
Income Tax - Current - Domestic
| 3.87M | 16.73M | 40.91M | 61.83M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 9.32M | 4.91M | (17.80M) | (9.45M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 39.48M | 83.08M | 71.41M | 163.89M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 39.48M | 83.08M | 71.41M | 163.89M | |
Net Income Growth
| -47.35% | +110.42% | -14.05% | +129.50% | |
Net Margin Growth
| +28.03% | +38.79% | +17.93% | +33.33% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 39.48M | 83.08M | 71.41M | 163.89M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 39.48M | 83.08M | 71.41M | 163.89M | |
EPS (Basic)
| 0.3819 | 0.8037 | 0.6719 | 1.3835 | |
EPS (Basic) Growth
| -47.28% | +110.45% | -16.40% | +105.91% | |
Basic Shares Outstanding
| 103.38M | 103.37M | 106.28M | 118.46M | |
EPS (Diluted)
| 0.3663 | 0.7459 | 0.6278 | 1.3117 | |
EPS (Diluted) Growth
| -48.10% | +103.63% | -15.83% | +108.94% | |
Diluted Shares Outstanding
| 107.80M | 111.38M | 113.75M | 124.94M | |
EBITDA
| 52.87M | 103.32M | 119.95M | 233.18M | |
EBITDA Growth
| +25.32% | +95.43% | +16.10% | +94.39% | |
EBITDA Margin
| +37.54% | +48.24% | +30.12% | +47.42% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 34.286 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.308 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 1.578 | |
| Last Quarter’s Earnings | 0.42 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.31 | Next Fiscal Year Estimate | 1.786 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 1 | 5 | 5 |
| Mean Estimate | 0.31 | 0.37 | 1.58 | 1.79 |
| High Estimates | 0.35 | 0.37 | 1.62 | 1.97 |
| Low Estimate | 0.21 | 0.37 | 1.48 | 1.54 |
| Coefficient of Variance | 18.42 | N/A | 3.60 | 10.08 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Astria Therapeutics Inc - CPRX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Astria Therapeutics Inc - CPRX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 6, 2025 | Brian Elsbernd Chief Compliance/Legal Officer | 188,564 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.93 per share | 4,323,772.52 |
| Mar 6, 2025 | Brian Elsbernd Chief Compliance/Legal Officer | 241,819 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.24 per share | 541,674.56 |
| Mar 6, 2025 | Brian Elsbernd Chief Compliance/Legal Officer | 188,564 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.23 per share | 4,380,341.72 |
| Mar 6, 2025 | Brian Elsbernd Chief Compliance/Legal Officer | 197,834 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.24 per share | 443,148.16 |
| Mar 6, 2025 | Brian Elsbernd Chief Compliance/Legal Officer | 1,062,339 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Brian Elsbernd Chief Compliance/Legal Officer | 1,009,084 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Jeff Del Carmen Chief Commercial Officer | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.89 per share | 0.00 |
| Feb 20, 2025 | Steven R. Miller Chief Op. & Scientific Officer | 1,524,509 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Preethi Sundaram Chief Strategy Officer | 678,432 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Richard John Daly President and CEO; Director | 269,764 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Richard John Daly President and CEO; Director | 271,338 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Donald A. Denkhaus Director | 495,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Steven R. Miller Chief Op. & Scientific Officer | 949,663 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Charles B. O'Keeffe Director | 208,274 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Charles B. O'Keeffe Director | 732,470 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | David S. Tierney Director | 208,274 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | David S. Tierney Director | 355,620 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Gary Ingenito Chief Med. & Reg. Officer | 1,015,282 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Gary Ingenito Chief Med. & Reg. Officer | 68,873 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Gary Ingenito Chief Med. & Reg. Officer | 71,308 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |